Time filter

Source Type

Ravenna, Italy

Casanova C.,Medical Oncology Unity | Verlicchi A.,Medical Oncology Unity | Mazza V.,Medical Oncology Unity | Dazzi C.,Medical Oncology Unity
Future Oncology | Year: 2015

We report the case of a HER2+ breast cancer patient, with early relapse, refractory to HER2-targeted therapy and treated with eribulin mesylate. The patient progressed during two different HER2 target therapies: trastuzumab as adjuvant/first-line treatment and lapatinib as second-line treatment. The patient underwent nine cycles of eribulin (1.23 mg/m2 days 1-8 every 3 weeks). The therapy was well tolerated. Restaging with computed tomography after the second cycle of treatment demonstrated stable disease. After nine cycles of eribulin therapy the patient experienced disease progression and she died 6 months later. This case report provides further insights regarding the use of eribulin mesylate as third-line treatment in a HER2+ breast cancer patient. © 2015 Future Medicine Ltd. Source

Discover hidden collaborations